Published in AIDS Weekly, March 22nd, 2004
"Viral entry inhibitors represent an emerging mode of therapy for human immunodeficiency virus type I (HIV-1) infection," scientists in New York noted. "PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates."
"PRO 542 binds to the viral surface glycoprotein gp120 and blocks attachment and entry of virus into CD4+ cells," J.N. Jacobson and colleagues at Mount Sinai Medical Center explained. "Previously, PRO 542 demonstrated antiviral activity without significant toxicity when tested at single doses ranging to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.